Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti-EGFR/IL-13R alpha 2 CAR T cell therapy - Tmunity Therapeutics/University of Pennsylvania

Drug Profile

Anti-EGFR/IL-13R alpha 2 CAR T cell therapy - Tmunity Therapeutics/University of Pennsylvania

Alternative Names: Anti-EGFR/IL-13Rα2 CAR T cell therapy; Anti-Epidermal growth factor receptor/ Interleukin 13 Receptor subunit alpha 2 CAR-T therapy; CART-EGFR-IL13Ra2; TmEGFR/IL13Rα2 01 CAR-T

Latest Information Update: 13 Mar 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tmunity Therapeutics; University of Pennsylvania
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Glioblastoma

Most Recent Events

  • 23 Feb 2023 Phase-I clinical trials in Glioblastoma (Recurrent, Combination therapy) in USA (IV) (NCT05168423)
  • 22 Feb 2023 Tmunity Therapeutics has been acquired by Kite Pharma
  • 19 Dec 2021 Tmunity Therapeutics and University of Pennsylvania plans a phase I trial in Glioblastoma (Combination therapy) (IV, infusion) in December 2021 (NCT05168423)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top